Jefferies Maintains Buy, $31 PT on Body Central
Jefferies reiterates its Buy rating and $31 price target on Body Central (NASDAQ: BODY) on positive pre-announcement for the fourth quarter.
Jefferies says, "BODY pre-announced 4Q sales numbers ahead of its presentation at the ICR conference later this week. Topline was better than expected and the company raised its EPS outlook to the high end of the prior range. We view this news very positively and remain buyers of this stock, especially given the current cheap valuation for a high growth name."
BODY closed at $23.15 per share on Monday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.